Syndax Pharmaceuticals focuses on developing an HDAC inhibitor for solid tumors and hematological tumors.
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 31, 2020 | Post-IPO Debt | $30M | 2 |
![]() |
— | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jul 1, 2021
![]() |
Seed | $1.10M | Blockchain | — |
Mar 20, 2019
![]() |
Seed | $2M | Cryptocurrency | Yes |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Post-IPO Debt |
|
Yes | Post-IPO Debt |